

January 03, 2025

**The Listing Department  
BSE Limited  
Phiroze Jeejebhoy Towers,  
Dalal Street, Fort,  
Mumbai – 400001  
BSE Scrip Code: 543427**

**The Listing Department  
National Stock Exchange of India Limited  
Exchange Plaza, 5<sup>th</sup> Floor  
Plot No. C/1, G Block,  
Bandra - Kurla Complex  
Bandra (East), Mumbai – 400051  
NSE Symbol: MEDPLUS**

Dear Sir/Madam,

**Sub: Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

We would like to inform that Optival Health Solutions Private Limited, the material subsidiary company has received one suspension order of Drug License for stores situated at Maharashtra. The Information as per SEBI circular dated July 13, 2023, are given below:

Name(s) of the Authority	Nature and details of the action(s) taken, initiated or order(s) passed	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	Details of the violation(s)/ contravention(s) committed or alleged to be committed	Impact on financial operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible
Asst. Commissioner Licensing authority, Food & Drug Administration's, Nagpur, Maharashtra,	Suspension of Drug License for fifteen days of a store situated at Mahal, Nagpur, Maharashtra.	Order received on 02.01.2025	Under Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945	Potential Revenue Loss of Rs~9.45 lacs.

Kindly take the same on records.

**For MedPlus Health Services Limited  
Manoj Kumar Srivastava**

**Company Secretary & Compliance Officer  
FCS 7460**